London-listed multinational drug manufacturer Hikma Pharmaceuticals PLC said that its chief executive officer, Riad Mishlawi, has left his position and resigned from its board by mutual agreement. The leadership change comes at a critical moment for the company, as it navigates operational challenges, market pressures, and investor concerns linked to performance and execution delays.

Following Mishlawi’s exit, Executive Chairman Said Darwazah is taking on the additional responsibility of interim Chief Executive Officer with immediate effect. The board confirmed a formal process to identify a permanent successor is under way. Chief Financial Officer Khalid Nabilsi has also been appointed to the board, which will take on an expanded role aimed at strengthening oversight and supporting the company’s strategic objectives as it transitions.

A Long Career at Hikma

Riad Mishlawi was leaving the company after a long stint of over 20 years at Hikma in different leadership roles. He had headed one of its most critical and complex business units, Hikma Injectables, for over a decade before he was appointed as CEO in September 2023. At the time of his appointment, he represented continuity because he possessed deep knowledge of the operational working of the company and long experience within it.

In statements concluding the announcement, Mishlawi described his decision as part of a move into retirement and expressed pride in the work accomplished during his career at Hikma. He also thanked employees and leadership colleagues and wished the company further success.

Market and Performance Pressures

Despite having a long association with the business, Mishlawi’s tenure as chief executive coincided with a period of heightened scrutiny from investors. The share price of Hikma has slumped on his watch, reflecting concerns about its profitability, execution risks, and delays to some key projects. The injectables segment, a substantial component of revenues and an important leg of its long-term growth strategy, has been a particular headache.

Among the operational issues that have weighed most heavily on the group has been delays at Hikma’s new US manufacturing facility, which was supposed to increase the group’s production capacity in high-margin injectable medicines. Construction and equipment difficulties have pushed the expected opening a number of years past forecasts, impacting investor confidence in the future revenue.

Later in 2024, the company updated its margin outlook and tightened its guidance, citing increased costs, manufacturing complexities, and slower-than-expected progress on expansion projects. Those added to leadership pressure and asked questions about execution and strategic timing.

Board Response & Interim Leadership

The board at Hikma has made it clear that this transition at the top is meant to stabilize the business, maintain momentum, and simultaneously allow for a permanent CEO to be located. This immediate return to the chief executive role by Said Darwazah, even on an interim basis, is reflective of experienced stewardship wanted at the board’s helm during uncertain times.

The highly influential Darwazah, of the founding family, has been CEO several times and is credited with leading Hikma’s international expansion, building its global identity. His familiarity with the business should reassure investors and employees as Hikma works through operational and strategic challenges.

Also, the appointment of Chief Financial Officer Khalid Nabilsi to the board signals a renewed focus on financial discipline and execution. By putting in place robust financial leadership at board level, Hikma aims at better alignment of capital allocation, operational performance, and long-term strategy.

Industry Background

The leadership change at Hikma comes as the whole pharmaceutical industry is under pressure globally. Makers of generic and injectable drugs face rising costs, a more rigorous regulatory environment, supply chain disruptions, and intensifying competition. These factors have made investors more sensitive to delays, missed targets, and margin volatility.

Therefore, changes in executive positions in major pharmaceutical companies are no longer termed routine transitions but a signal of strategic recalibration. In the case of Hikma, such a change underscores the need for execution and delivery at a time when confidence needs to be restored for growth to be unlocked from the core businesses.

Looking Ahead

The board confirmed that the company’s current, near-term financial guidance remained unchanged and its strategic priorities were an ongoing focus on operational efficiency, disciplined investment in growth opportunities, and long-term growth. The search for a new permanent CEO will be closely watched by investors, analysts, and employees alike, as the next leader is expected to take on execution challenges while positioning Hikma for sustainable expansion. The departure of Riad Mishlawi marks a momentous moment in the corporate history of Hikma. Much will depend on how interim leadership manages the transition as it heads into its next chapter, and how quickly a new chief executive can restore momentum in an unforgiving and competitive global market.